China Resources Double-Crane Pharmaceutical (600062) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

600062 China Resources Double-Crane Pharmaceutical

Watchlist

23.00
-0.21-0.90%

Market Closed Oct 15 15:00 CST

23.90BMarket Cap17.14P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

China Resources Double-Crane Pharmaceutical (600062.SH): Tadalafil Citrate Tablets Obtained Drug Supplementary Application Approval Letter.
On October 14, Gelonghui announced that China Resources Double-Crane Pharmaceutical (600062.SH) disclosed that its wholly-owned subsidiary, China Resources Saikopharmaceutical Co., Ltd., has received the National Medical Products Administration's approval for the supplementary application of 25mg sildenafil citrate tablets with a 'Drug Supplementary Application Approval Letter'. This pharmaceutical is used for the treatment of erectile dysfunction.
Gelonghui FinanceOct 14 05:01 ET
China Grants CR Double-Crane Pharma's API Approval for Epilepsy Drug Ingredients
MT NewswiresSep 11 23:00 ET
China resources double-crane pharmaceutical (600062.SH): Propionic acid and sodium propionate chemical raw materials application for listing approved
China Resources Double-Crane (600062.SH) announced that its subsidiary, Hunan Xiangzhong Pharmaceutical Co., Ltd., has received...
Zhitong FinanceSep 11 05:10 ET
CR Double-Crane Pharmaceutical Unit's Omeprazole Sodium for Injection Passes Regulatlry Evaluation
MT NewswiresSep 9 00:02 ET
Double-Crane Pharma Gets China Clinical Trial Nod for Menstrual Dysfunction Drug
MT NewswiresSep 5 08:16 ET
Double-Crane Pharma's Leukemia Medication Passes Generic Drug Evaluation in China
MT NewswiresSep 5 08:14 ET

Comments

Moomoo AI

Mar 23 20:06

Analysts show less optimism post-results due to lowered revenue forecasts and minor EPS downgrade. Despite growth acceleration, China Resources Double-Crane PharmaceuticalLtd is predicted to lag behind industry average. Concerns arise as EPS estimates are reduced, indicating potential business challenges.

Earnings Update: Here's Why Analysts Just Lifted Their China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Price Target To CN¥24.91

Moomoo AI

Mar 4 17:26

Despite a recent boost in China Resources Double-Crane Pharmaceutical's stock, its low P/E ratio suggests investors expect limited future growth. The company's forecast growth is lower than the wider market, indicating a potential lack of strong share price rise in the near future.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Moomoo AI

Jan 30 22:38

The company's five-year earnings growth track record has boosted its market reputation. Despite modest recent returns, the five-year total shareholder return is impressive at 13% per year. The stock's peak may have passed, or the price may be stabilizing as the business continues to perform.

China Resources Double-Crane PharmaceuticalLtd's (SHSE:600062) 13% CAGR Outpaced the Company's Earnings Growth Over the Same Five-year Period

Moomoo AI

Dec 19, 2023 20:27

Investors foresee restrained growth for China Resources Double-Crane PharmaceuticalLtd, which may be affecting its P/E ratio. Current circumstances could obstruct a substantial share price rise.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Looks Inexpensive But Perhaps Not Attractive Enough

Moomoo AI

Oct 23, 2023 01:07

Despite recent stock price drop, the company's long-term prospects seem positive with steady EPS growth and a TSR surpassing share price. The recent sell-off could be a potential opportunity if long-term growth trends persist.

China Resources Double-Crane PharmaceuticalLtd's (SHSE:600062) Earnings Growth Rate Lags the 9.2% CAGR Delivered to Shareholders

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

600062 China Resources Double-Crane Pharmaceutical

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target